[PETGAS] QoQ Annualized Quarter Result on 30-Jun-2023 [#2]

Announcement Date
25-Aug-2023
Admission Sponsor
-
Sponsor
-
Financial Year
31-Dec-2023
Quarter
30-Jun-2023 [#2]
Profit Trend
QoQ- 7.21%
YoY- 12.7%
View:
Show?
Annualized Quarter Result
31/03/24 31/12/23 30/09/23 30/06/23 31/03/23 31/12/22 30/09/22 CAGR
Revenue 6,475,236 6,445,423 6,483,449 6,624,626 6,699,780 6,160,176 6,036,406 4.78%
PBT 2,389,384 2,386,015 2,370,050 2,366,108 2,227,748 2,269,368 2,322,540 1.90%
Tax -500,208 -484,976 -456,150 -477,580 -434,576 -510,900 -594,053 -10.82%
NP 1,889,176 1,901,039 1,913,900 1,888,528 1,793,172 1,758,468 1,728,486 6.09%
-
NP to SH 1,826,588 1,819,600 1,837,345 1,819,100 1,696,708 1,645,446 1,643,866 7.27%
-
Tax Rate 20.93% 20.33% 19.25% 20.18% 19.51% 22.51% 25.58% -
Total Cost 4,586,060 4,544,384 4,569,549 4,736,098 4,906,608 4,401,708 4,307,920 4.25%
-
Net Worth 13,589,931 13,555,105 13,477,736 13,325,177 13,143,925 13,148,080 13,115,233 2.39%
Dividend
31/03/24 31/12/23 30/09/23 30/06/23 31/03/23 31/12/22 30/09/22 CAGR
Div 1,266,388 1,424,687 1,319,154 1,266,388 1,266,388 1,424,687 1,319,154 -2.68%
Div Payout % 69.33% 78.30% 71.80% 69.62% 74.64% 86.58% 80.25% -
Equity
31/03/24 31/12/23 30/09/23 30/06/23 31/03/23 31/12/22 30/09/22 CAGR
Net Worth 13,589,931 13,555,105 13,477,736 13,325,177 13,143,925 13,148,080 13,115,233 2.39%
NOSH 1,978,732 1,978,732 1,978,732 1,978,732 1,978,732 1,978,732 1,978,732 0.00%
Ratio Analysis
31/03/24 31/12/23 30/09/23 30/06/23 31/03/23 31/12/22 30/09/22 CAGR
NP Margin 29.18% 29.49% 29.52% 28.51% 26.76% 28.55% 28.63% -
ROE 13.44% 13.42% 13.63% 13.65% 12.91% 12.51% 12.53% -
Per Share
31/03/24 31/12/23 30/09/23 30/06/23 31/03/23 31/12/22 30/09/22 CAGR
RPS 327.24 325.74 327.66 334.79 338.59 311.32 305.06 4.78%
EPS 92.32 91.96 92.85 91.94 85.76 83.16 83.08 7.27%
DPS 64.00 72.00 66.67 64.00 64.00 72.00 66.67 -2.68%
NAPS 6.868 6.8504 6.8113 6.7342 6.6426 6.6447 6.6281 2.39%
Adjusted Per Share Value based on latest NOSH - 1,978,732
31/03/24 31/12/23 30/09/23 30/06/23 31/03/23 31/12/22 30/09/22 CAGR
RPS 327.24 325.74 327.66 334.79 338.59 311.32 305.06 4.78%
EPS 92.32 91.96 92.85 91.94 85.76 83.16 83.08 7.27%
DPS 64.00 72.00 66.67 64.00 64.00 72.00 66.67 -2.68%
NAPS 6.868 6.8504 6.8113 6.7342 6.6426 6.6447 6.6281 2.39%
Price Multiplier on Financial Quarter End Date
31/03/24 31/12/23 30/09/23 30/06/23 31/03/23 31/12/22 30/09/22 CAGR
Date 29/03/24 29/12/23 29/09/23 30/06/23 31/03/23 30/12/22 30/09/22 -
Price 17.62 17.40 16.84 16.70 16.48 17.12 16.50 -
P/RPS 5.38 5.34 5.14 4.99 4.87 5.50 5.41 -0.36%
P/EPS 19.09 18.92 18.14 18.17 19.22 20.59 19.86 -2.59%
EY 5.24 5.28 5.51 5.50 5.20 4.86 5.03 2.76%
DY 3.63 4.14 3.96 3.83 3.88 4.21 4.04 -6.87%
P/NAPS 2.57 2.54 2.47 2.48 2.48 2.58 2.49 2.12%
Price Multiplier on Announcement Date
31/03/24 31/12/23 30/09/23 30/06/23 31/03/23 31/12/22 30/09/22 CAGR
Date 29/05/24 27/02/24 20/11/23 25/08/23 22/05/23 16/02/23 14/11/22 -
Price 18.30 18.06 17.18 17.06 16.94 17.50 16.94 -
P/RPS 5.59 5.54 5.24 5.10 5.00 5.62 5.55 0.47%
P/EPS 19.82 19.64 18.50 18.56 19.76 21.04 20.39 -1.87%
EY 5.04 5.09 5.40 5.39 5.06 4.75 4.90 1.89%
DY 3.50 3.99 3.88 3.75 3.78 4.11 3.94 -7.58%
P/NAPS 2.66 2.64 2.52 2.53 2.55 2.63 2.56 2.58%

PBT = Profit before Tax, NP = Net Profit, NP to SH = Net Profit Attributable to Shareholder, Div = Dividend, NP Margin = Net Profit Margin, ROE = Return on Equity, NOSH = Number of Shares, RPS = Revenue per Share, EPS = Earning Per Share, DPS = Dividend Per Share, NAPS = Net Asset Per Share, EOQ = End of Quarter, ANN = Announcement, P/RPS = Price/Revenue per Share, P/EPS = Price/Earning per Share, P/NAPS = Price/Net Asset per Share, EY = Earning Yield, DY = Dividend Yield.

NOSH is estimated based on the NP to SH and EPS. Div is an estimated figure based on the DPS and NOSH. Net Worth is an estimated figure based on the NAPS and NOSH.

Div Payout %, NP Margin, ROE, DY, QoQ & YoY figures in Percentage; RPS, EPS & DPS's figures in Cent; and NAPS's figures in Dollar.

All figures in '000 unless specified.

Discussions
Be the first to like this. Showing 0 of 0 comments

Post a Comment